BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids. The sequence was originally identified within a larger protein fragment found in human gastric juice, and since the late 1990s it has been the subject of dozens of animal studies focused on musculoskeletal healing, gastrointestinal repair, and wound closure.
The research interest in BPC-157 centers largely on its apparent ability to upregulate growth factor expression, particularly vascular endothelial growth factor (VEGF) and its receptor VEGFR2. In rodent studies, animals given BPC-157 following induced ligament and tendon injuries showed accelerated collagen organization compared to untreated controls. A 2011 study published in the Journal of Orthopaedic Research documented improved tendon-to-bone healing in rats treated with the peptide after surgical detachment of the Achilles tendon.
Gastrointestinal applications have also been studied. Research from the laboratory of Predrag Sikiric at the University of Zagreb has examined BPC-157 in models of colitis, short bowel syndrome, and gastric lesion healing. These studies consistently report accelerated mucosal healing, though the exact mechanism remains an active area of inquiry. One proposed pathway involves modulation of the nitric oxide system, which plays a central role in regulating blood flow and tissue repair in the GI tract.
It is worth noting that while the animal literature is substantial, BPC-157 has not completed large-scale human clinical trials as of the time of writing. The peptide remains classified as a research compound and is sold strictly for laboratory and investigational use. Researchers interested in reviewing the primary literature can access the relevant studies through PubMed using author searches for Sikiric P or the compound name directly.
All products sold by Vanguard Research Labs are intended exclusively for qualified researchers and are not for human consumption.